CEO reflection on 2016

Dear shareholders, colleagues and friends

I would like to express my gratitude for all the support and hard work that has made 2016 a great year for Alligator. First I would like to thank our faithful shareholders for always believing in Alligator, and it is a pleasure for us to have been able to deliver on the high expectations. I feel privileged to have been part of Alligator´s success over the last year, and very excited to lead the company ahead.

Alligator has progressed the drug development projects rapidly during 2016 and today holds a strong and competitive pipeline. The first clinical trial of ADC-1013 is now nearly completed, and a second clinical phase 1 trial of intravenous ADC-1013, sponsored by Janssen Biotech, has been initiated. ATOR-1015 is in late pre-clinical development and the first important steps for the manufacturing of clinical material have been successfully completed and further de-risked this highly innovative bispecific project. Moreover, we have progressed two additional compounds to a point that will allow initiation of pre-clinical development and manufacturing during 2017.

Our financial situation is strong after receiving a milestone for ADC-1013 and issuing shares at the listing at Nasdaq Stockholm in November. This has allowed us to fully invest in the pipeline and to establish Alligator as a key player within our field of tumor-directed immunotherapy.

We have also had the pleasure of welcoming a large number of new colleagues to Alligator during 2016. The expertise, passion and commitment of all the amazing people at Alligator has been the key driver for our success and will continue to be of critical importance over the years to come.

Thank you all for your contributions in 2016 and best wishes for 2017!
Per Norlén